Award-winning study confirms Medimaps Group new AI software accurately assesses bone fragility from routine X-rays
Medimaps announced the presentation of new data on its AI deep learning software model to opportunistically detect bone fragility from conventional X-ray imaging, at the American Society for Bone and Mineral Research annual congress (ASBMR) .
TBS Osteo: a trusted bone health solution in the world’s top hospitals
Newsweek’s World’s Best Hospitals 2023 list offers a fitting moment to reflect on TBS Osteo™’s reach: the software is present in more than half of these top 250 hospitals, and trusted by 15 of the top hospitals on the list.
Medimaps receives EU certification under the Medical Device Regulation
Medimaps has received Medical Device Regulation (MDR) certification from its notified body BSI (CE 2797) for its management system and product portfolio.
Medimaps Group appoints Meinhard F. Schmidt as Board Chairman; adds Anne Le Grand and five additional board members
Meinhard F. Schmidt, an international MedTech/BioTech and digital health executive with 25+ years of experience, has been named Board Chairman.
Medical reimbursement now available for Trabecular Bone Score (TBS), an advanced medtech solution with artificial intelligence capabilities, for osteoporosis fracture risk assessment
Medimaps — the creator of TBS® (Trabecular Bone Score®), the global standard in bone microarchitecture assessment — today announced that CMS reimbursement is now available for TBS Osteo™ for DXA and X-ray imaging.
Medimaps Group raises $20 million to expand and commercialize AI product portfolio for bone health assessment utilizing routine medical images
Medimaps announced that it has secured $20 million in an institutional investment round led by Swisscanto Invest by Zürcher Kantonalbank, alongside Swiss Entrepreneurs Fund, Swisscom Ventures, and Verve Ventures. The funds will be used to expand Medimaps’ product portfolio with the development and market launch of its patented AI applications for bone health assessment in the US, Europe, Asia, and Latin America. TBS Osteo™ will receive medical reimbursement in the US beginning January 1, 2022.